Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2019-06-27 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Zafgen, Inc. dated June 13, 2019. The key content is under Item 5.07, which details the submission of matters to a vote of security holders at the company's Annual Meeting of Stockholders held on June 13, 2019. It includes voting results for director elections and ratification of the independent auditor. There is no financial data or detailed report content, only the official voting results from the shareholder meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4151 characters, which is consistent with a voting results announcement rather than a full report or proxy statement. Therefore, the correct classification is DVA with high confidence.
2019-06-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.